Nim­bus is back for more, rais­ing $210M to fu­el pipeline sev­en months af­ter $4B Take­da deal

What kind of biotech com­pa­ny re­turns bil­lions to its in­vestors with­out ever open­ing a lab, com­mer­cial­iz­ing a drug, or go­ing pub­lic with an IPO?

Nim­bus Ther­a­peu­tics. Af­ter rais­ing $125 mil­lion just a year ago and sell­ing a still-ex­per­i­men­tal pill to Take­da Phar­ma­ceu­ti­cal in a deal ear­li­er this year that could be worth as much as$6 bil­lion, the small Boston-based biotech is back for more.

On Wednes­day, Nim­bus an­nounced that it raised $210 mil­lion in pri­vate fi­nanc­ing, in­clud­ing from first-timer GV (for­mer­ly known as Google Ven­tures) and re­turn­ing in­vestors that in­clude SR One, At­las Ven­ture, and Gates Fron­tier — Bill Gates’ ven­ture cap­i­tal firm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER